ArticleComputer methods and programs in biomedicine2013
pocrm: an R-package for phase I trials of combinations of agents.
Article in Computer methods and programs in biomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Joint time-to-event partial order continual reassessment method and Joint time-to-event Bayesian logistic regression model: Statistical designs for dual agent phase I/II dose finding studies with late-onset toxicity and activity outcomes.Statistical methods in medical research · 2026Article
- Toxicity Adaptive Lists Design: A Practical Design for Phase I Drug Combination Trials in Oncology.JCO precision oncology · 2024Article
- Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies.Journal of applied statistics · 2023Review
- Two-dimensional calibration-free odds design for phase I drug-combination trials.Frontiers in oncology · 2023Article
- A benchmark for dose-finding studies with unknown ordering.Biostatistics (Oxford, England) · 2022Article
- A surface-free design for phase I dual-agent combination trials.Statistical methods in medical research · 2020Article
- CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.Computer methods and programs in biomedicine · 2019Article
- Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.The AAPS journal · 2018Article
- Implementation of adaptive methods in early-phase clinical trials.Statistics in medicine · 2017Review
- Practical designs for Phase I combination studies in oncology.Journal of biopharmaceutical statistics · 2016Review
- A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.Statistics in medicine · 2015Article
- Comments on 'competing designs for drug combination in phase I dose-finding clinical trials' by M-K. Riviere, F. Dubois, S. Zohar.Statistics in medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This paper presents the R package pocrm for implementing and simulating the partial order continual reassessment method (PO-CRM; [1,2]) in Phase I trials of combinations of agents. The aim of this article is to illustrate, through examples of the pocrm package, how the PO-CRM works and how its operating characteristics can inform clinical trial investigators. This should promote the use of the PO-CRM in designing and conducting dose-finding Phase I trials of combinations of agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.